As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential vaccines and specialty medicines that help us to get ahead of disease together
Number of phase I programmes started in 2023
5
Number of assets in phase III/registration in 2023
3
Major aprrovals
0
vaccines and medicines in the pipeline
2
Cell therapy
lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum .
Cell therapy
lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum .
Cell therapy
lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum .
Cell therapy
lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum lorem ipsum .
